Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease

NCT03056495 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Insufficient Recruitment

Conditions

Alzheimer Disease

Interventions

DRUG: N-hydroxy-N'-phenyl-octanediamide (Vorinostat)

Sponsor

German Center for Neurodegenerative Diseases (DZNE)

Collaborators

[object Object]
[object Object]